To hear about similar clinical trials, please enter your email below
Trial Title:
Comparison of Image Quality Between "Double Low Dose" Liver CT and Standard Liver CT
NCT ID:
NCT05790590
Condition:
Metastasis to Liver
Colorectal Cancer
Conditions: Official terms:
Colorectal Neoplasms
Conditions: Keywords:
CT
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Diagnostic
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Double low dose CT
Description:
Simultaneous reduction of both radiation dose and contrast media dose
Arm group label:
Double low dose CT
Intervention type:
Diagnostic Test
Intervention name:
Standard dose CT
Description:
CT with standard radiation dose and contrast media dose
Arm group label:
Standard dose CT
Summary:
In patients with malignancies, contrast-enhanced abdominal CT (hereafter abdominal CT)
plays an important role in detecting carcinoma recurrence and assessing treatment
response. In this study, we aim to investigate whether such a "double low" dose CT is
feasible in patients with liver metastases of colorectal cancer using a vendor-agnostic
artificial intelligence-based noise reduction and contrast enhancement software.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- colorectal cancer (CRC) patients
- on surveillance or monitoring for liver metastasis (of CRC)
Exclusion Criteria:
- any relative or absolute contra-indication of CECT
- diffuse infiltrative type of liver metastasis or on monitoring for too many liver
lesions
Gender:
All
Minimum age:
20 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Seoul National University Hospital
Address:
City:
Seoul
Zip:
03080
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Hyuna Jung, RN
Phone:
82-2-2072-4177
Email:
jha5375@snu.ac.kr
Investigator:
Last name:
Jeong Min Lee, MD
Email:
Principal Investigator
Start date:
May 30, 2023
Completion date:
June 30, 2025
Lead sponsor:
Agency:
Seoul National University Hospital
Agency class:
Other
Collaborator:
Agency:
Bayer
Agency class:
Industry
Source:
Seoul National University Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05790590
